Cargando…

Long-term effect of α(1)-antitrypsin augmentation therapy on the decline of FEV(1) in deficient patients: an analysis of the AIR database

BACKGROUND: Patients with ZZ (Glu342Lys) α-1-antitrypsin deficiency (ZZ-AATD) who received augmentation therapy with α-1-antitrypsin (AAT) in randomised controlled trials over 2–3 years failed to show a significant reduction of the annual decline of forced expiratory volume in 1 s (FEV(1)). METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schouten, Iris G.M., Kasteleyn, Marise J., Tsonaka, Roula, Bals, Robert, Turner, Alice C., Ferrarotti, Ilaria, Corsico, Angelo G., Lara, Beatriz, Miravitlles, Marc, Stockley, Robert A., Stolk, Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2021
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381156/ https://www.ncbi.nlm.nih.gov/pubmed/34435030 http://dx.doi.org/10.1183/23120541.00194-2021

Ejemplares similares

Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach
por: Stockley, Robert A, et al.
Publicado: (2013)

Update on α(1)-antitrypsin deficiency
por: Ferrarotti, Ilaria, et al.
Publicado: (2018)

Decline in FEV(1) and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency
por: Hiller, Adriana-Maria, et al.
Publicado: (2019)

Therapeutic efficacy of alpha-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry
por: Stockley, Robert A, et al.
Publicado: (2010)

The prevalence of bronchiectasis in patients with alpha-1 antitrypsin deficiency: initial report of EARCO
por: Stockley, Robert A., et al.
Publicado: (2023)

There is No Fast Track to Identify Fast Decliners in Alpha-1 Antitrypsin Deficiency by Spirometry: A Longitudinal Study of Repeated Measurements
por: Stockley, James A, et al.
Publicado: (2021)

Health status decline in α-1 antitrypsin deficiency: a feasible outcome for disease modifying therapies?
por: Stockley, Robert A., et al.
Publicado: (2018)

The Course of AαVal541 as a Proteinase 3 Specific Neo-Epitope after Alpha-1-Antitrypsin Augmentation in Severe Deficient Patients
por: Schouten, Iris G. M., et al.
Publicado: (2021)

Protocol for the EARCO Registry: a pan-European observational study in patients with α(1)-antitrypsin deficiency
por: Greulich, Timm, et al.
Publicado: (2020)

COVID-19 infection in severe Alpha 1-antitrypsin deficiency: Looking for a rationale
por: Ferrarotti, I., et al.
Publicado: (2021)

Clinical considerations in individuals with α(1)-antitrypsin PI*SZ genotype
por: McElvaney, Gerard N., et al.
Publicado: (2020)

Alpha-1 Antitrypsin Deficiency: The Learning Goes On
por: Stockley, Robert. A.
Publicado: (2020)

Alpha-1 Antitrypsin Augmentation Therapy Improves Survival in Severely Deficient Patients with Predicted FEV1 Between 10% and 60%: A Retrospective Analysis of the NHLBI Alpha-1 Antitrypsin Deficiency Registry
por: Rahaghi, Franck F, et al.
Publicado: (2020)

Molecular diagnosis of alpha1‐antitrypsin deficiency: A new method based on Luminex technology
por: Ottaviani, Stefania, et al.
Publicado: (2020)

Protease-Specific Biomarkers to Analyse Protease Inhibitors for Emphysema Associated with Alpha 1-Antitrypsin Deficiency. An Overview of Current Approaches
por: Viglio, Simona, et al.
Publicado: (2021)

Rate of Decline of FEV(1) as a Biomarker of Survival?
por: Papi, Alberto, et al.
Publicado: (2021)

Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications
por: Chapman, Kenneth R, et al.
Publicado: (2018)

Improving the Laboratory Diagnosis of M-like Variants Related to Alpha1-Antitrypsin Deficiency
por: Barzon, Valentina, et al.
Publicado: (2022)

Case-finding for alpha1-antitrypsin deficiency in Kazakh patients with COPD
por: Zhumagaliyeva, Ardak, et al.
Publicado: (2017)

Exome Sequencing Reveals Immune Genes as Susceptibility Modifiers in Individuals with α(1)-Antitrypsin Deficiency
por: Rigobello, Chiara, et al.
Publicado: (2019)

Exploring the optimum approach to the use of CT densitometry in a randomised placebo-controlled study of augmentation therapy in alpha 1-antitrypsin deficiency
por: Parr, David G, et al.
Publicado: (2009)

Monocytes and Macrophages in Alpha-1 Antitrypsin Deficiency
por: Belchamber, Kylie B R, et al.
Publicado: (2020)

Adipose Mesenchymal Extracellular Vesicles as Alpha-1-Antitrypsin Physiological Delivery Systems for Lung Regeneration
por: Bari, Elia, et al.
Publicado: (2019)

New Patient-Centric Approaches to the Management of Alpha-1 Antitrypsin Deficiency
por: Chorostowska-Wynimko, Joanna, et al.
Publicado: (2020)

The Biological Effects of Double-Dose Alpha-1 Antitrypsin Augmentation Therapy. A Pilot Clinical Trial
por: Campos, Michael A., et al.
Publicado: (2019)

Improving the Lives of Patients with Alpha-1 Antitrypsin Deficiency
por: Sandhaus, Robert A, et al.
Publicado: (2020)

Obstructive sleep apnoea accelerates FEV(1) decline in asthmatic patients
por: Wang, Tsai-Yu, et al.
Publicado: (2017)

Alpha-1 antitrypsin (AAT) augmentation therapy in individuals with the PI*MZ genotype: a pro/con debate on a working hypothesis
por: Barjaktarevic, Igor, et al.
Publicado: (2021)

Beyond FEV(1) in COPD: a review of patient-reported outcomes and their measurement
por: Jones, Paul, et al.
Publicado: (2012)

Lower FEV(1) in non-COPD, nonasthmatic subjects: association with smoking, annual decline in FEV(1), total IgE levels, and TSLP genotypes
por: Masuko, Hironori, et al.
Publicado: (2011)

Systematic review of the evidence relating FEV(1 )decline to giving up smoking
por: Lee, Peter N, et al.
Publicado: (2010)

Risk factors for FEV(1) decline in mild COPD and high-risk populations
por: Chen, Shujing, et al.
Publicado: (2017)

Reliability of FEV(1)/FEV(6) to Diagnose Airflow Obstruction Compared with FEV(1)/FVC: The PLATINO Longitudinal Study
por: Perez-Padilla, Rogelio, et al.
Publicado: (2013)

Impact of COVID-19 in Patients With Severe Alpha-1 Antitrypsin Deficiency: The IMCA1 Study of the EARCO Clinical Research Collaboration
por: Parr, David G., et al.
Publicado: (2022)

Impact of the COVID-19 pandemic on well-being and quality of life of patients with alpha-1-antitrypsin deficiency
por: Werdecker, Catherina, et al.
Publicado: (2023)

Fixed Cut-Off for FEV1/FEV6 and FEV6 in Detection of Obstructive and Restrictive Patterns
por: Aghili, Rokhsareh, et al.
Publicado: (2013)

Clinical and functional characteristics of individuals with alpha-1 antitrypsin deficiency: EARCO international registry
por: Miravitlles, Marc, et al.
Publicado: (2022)

Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency
por: Petrache, Irina, et al.
Publicado: (2009)

Hereditary alpha-1-antitrypsin deficiency and its clinical consequences
por: Fregonese, Laura, et al.
Publicado: (2008)

Correction: Clinical and functional characteristics of individuals with alpha-1 antitrypsin deficiency: EARCO international registry
por: Miravitlles, Marc, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jrvdt0gni22qhvu5enas8mpmga